Conference Coverage

MicroRNAs flag liver damage in HIV-, HCV-infected persons


 

REPORTING FROM CROI


Of the 13 miRNAs, two, labeled miR-99a-5p and miR-100-5p, which belong to the same family of miRNAs, were found to be significantly upregulated in patients with HIV and HCV coinfections that later progressed to liver cirrhosis “even those these patients exhibited no liver fibrosis at the time of sampling,” he said

The two culprit miRNAs were significantly correlated with ALT and AST levels, as well as the degree of liver fibrosis.

A comparison of samples from patients with HIV monoinfection who had elevated ALT or focal nodular hyperplasia with those of patients with HIV infection but normal ALT levels showed that two other miRNAs, miR-122-3p and miR-193b-5p, were highly and significantly upregulated, and correlated with both aminotransferase and liver fibrosis levels.

“This study demonstrates the potential of microRNAs as biomarkers of liver injury progression in HIV-1 infected patients,” Dr. Martinez concluded.

The Spanish Instituto de Salud Carlos III and the Spanish AIDS network funded the study. Dr. Martinez reported having no conflicts of interest.

SOURCE: Martinez MA et al. CROI 2018, abstract 639.

Pages

Recommended Reading

HCV screening, care inadequate for young adults who use opioids nonmedically
MDedge Infectious Disease
Inflammatory markers predict vaccine response in HCV, HIV
MDedge Infectious Disease
Viremic suppression linked to decreased MACE rate in patients with HCV-cirrhosis
MDedge Infectious Disease
ACIP unanimously recommends HEPLISAV-B
MDedge Infectious Disease
HCV infection tied to premature ovarian senescence and a high miscarriage rate
MDedge Infectious Disease
NASH rapidly overtaking hepatitis C as cause of liver cancer
MDedge Infectious Disease
Bioengineered liver models screen drugs and study liver injury
MDedge Infectious Disease
Alcohol dependence may accelerate aging, frontal cortical deficits
MDedge Infectious Disease
HIV+ dialysis patients: Differential survival by race compared with HIV/HCV coinfection
MDedge Infectious Disease
Switching to tenofovir alafenamide may benefit HBV patients
MDedge Infectious Disease